Thymosin Alpha-1 and LL-37
Does pairing thymosin alpha-1 with LL-37 do anything for chronic infections, and what is the risk?
Reviewed by the amino101 editorial team. .
Also searched as TA1 LL-37 stack, thymosin alpha 1 and LL37, immune peptide stack, Lyme peptide stack.
Thymosin alpha-1 is a 28 amino acid peptide originally isolated from the thymus that primes T cells and dendritic cells. It is a licensed drug in much of the world for chronic hepatitis B and immune support, and in the research market it is used for infections, immune weakness and general resilience.
LL-37 is the only human antimicrobial peptide of the cathelicidin family, a 37 amino acid fragment that white blood cells and skin cells release to kill microbes and break up biofilms. Research is almost entirely in test tubes and animals, with one small topical trial in leg ulcers. Injected LL-37 has essentially no human safety data.
Thymosin alpha-1 and LL-37 are stacked because one is thought to train the immune system and the other to kill microbes directly. Thymosin alpha-1 is a 28 amino acid peptide that activates dendritic cells and pushes T cells toward the response that handles viruses and tumors. It is an approved drug in more than 30 countries for hepatitis B and as a vaccine adjuvant, with randomized trials behind it and a clean safety record across thousands of patients. LL-37 is the human antimicrobial peptide of the cathelicidin family, a 37 amino acid fragment that white blood cells release to punch holes in bacterial membranes and break up biofilms. Its research is almost entirely in test tubes and animals. The one human trial was topical, on venous leg ulcers, at low concentrations. Injected LL-37 has no published human safety data, no pharmacokinetic study and no trial by any route for any infection. No trial has tested the pair.
The combination circulates in Lyme, mold, chronic fatigue and long infection forums, usually with a story about resetting the immune system and clearing biofilms. This page separates the two halves, because they are not alike. One is a licensed medicine with modest, inconsistent benefits and a good safety profile; the other is an experiment that causes significant injection site inflammation in most people and is a known driver of psoriasis and lupus when it ends up in the wrong place. Both are prohibited by WADA and both were placed in FDA Category 2 in 2023. For the compound that thymosin alpha-1 is most often confused with, see thymosin alpha-1 vs TB-500. Everything here is educational background, not a treatment for anything.
Why people combine Thymosin Alpha-1 and LL-37
Thymosin alpha-1 works through toll-like receptors on dendritic cells, mainly TLR2 and TLR9, pushing them to present antigen and driving T cells toward a Th1 response, with more interleukin-2, interferon gamma and natural killer activity. LL-37 is the innate side: a positively charged peptide that disrupts bacterial membranes, binds endotoxin and attracts neutrophils and monocytes. The idea is that one sharpens the response and the other does the killing. It is a coherent story with no study behind it.
LL-37 prevents Pseudomonas biofilm formation and breaks down established biofilms in culture, at concentrations below what it takes to kill the bacteria. That finding is the whole basis for its use in chronic sinus, gut and Lyme protocols. Nobody has shown that a subcutaneous dose reaches any infection site in a useful amount; serum breaks LL-37 down quickly and binds it to apolipoprotein, which is why systemic antimicrobial effect from an injection is doubtful.
Six months of 1.6 mg twice weekly improved virological response in chronic hepatitis B in several randomized trials, though not all. The ETASS sepsis trial in 361 patients found a mortality trend that did not reach significance. Older adults and dialysis patients given it around flu and hepatitis B vaccines made more antibody. These are modest results in defined conditions. Community claims about curing chronic Lyme or long COVID go well beyond them, and there is no controlled evidence for either.
Anyone with psoriasis, rosacea, lupus or another autoimmune condition has a specific reason to avoid LL-37, which is implicated as a driver of inflammation in those diseases, and a general reason to be careful with thymosin alpha-1, which raises Th1 activity. Transplant recipients are excluded from thymosin alpha-1 on its own label. If the problem is an undiagnosed chronic infection, the useful next step is diagnosis, not two peptides.
Thymosin Alpha-1 and LL-37 dosage and protocol
What appears in research and community protocols for each compound in the stack. Not a prescription.
| Peptide | Dosage | Frequency | Timing and route |
|---|---|---|---|
| Thymosin Alpha-1 | 0.5 to 1.6 mg | 2 to 3 times weekly; the approved schedule is 1.6 mg twice weekly | subcutaneous, belly or thigh, any time of day, spaced 3 to 4 days apart |
| LL-37 | 50 to 125 mcg | once daily, or every other day if the injection site reacts; start at 50 mcg | subcutaneous in a separate syringe, rotating sites every dose because of local inflammation |
The two halves run on different clocks. Thymosin alpha-1 is used for 4 to 12 weeks in community protocols and 6 months continuously in the hepatitis B labeling. LL-37 runs 2 to 6 weeks, partly because injection site reactions accumulate and partly because there is no safety basis for anything longer. A common pattern is a short LL-37 block inside a longer thymosin alpha-1 course, then 4 to 8 weeks off both.
- •The LL-37 numbers come from vendors and forums. No human study has tested any injected dosage, so they describe what people use rather than what works.
- •The thymosin alpha-1 dosage does not change because it is stacked. 1.6 mg is the trial dose; community protocols often sit at 0.5 to 1 mg for general use. A 5 mg vial in 2 mL gives 2.5 mg per mL, so 1.6 mg is 64 units on an insulin syringe.
- •LL-37 doses are tiny in volume: 50 mcg from a 2.5 mg per mL solution is 2 units, which is hard to measure accurately. Diluting further helps.
- •Short daily thymosin alpha-1 courses of 5 to 7 days around an acute illness are borrowed from the sepsis trial design and are the only part of this stack with a trial analogue.
Work out syringe units for any of these in the dosage calculator.
Can you mix Thymosin Alpha-1 and LL-37 in one syringe?
Keep these in separate syringes. There is no stability data on the mixture, but the practical reason is diagnostic: LL-37 causes redness, warmth, swelling and sometimes a welt the size of a coin at most injection sites, and thymosin alpha-1 occasionally causes redness of its own. Mixing them makes it impossible to tell which compound a reaction belongs to, and LL-37 reactions are the ones that decide whether the stack continues. Both reconstitute in bacteriostatic water and keep in the fridge for up to 4 weeks. Vendors sell them as separate vials rather than as a blend, which is one of the few sensible things about this pairing. The reconstitution guide covers the volumes.
What to expect, week by week
- Day 1 to 3
Redness, warmth, swelling and soreness at LL-37 injection sites in most people, sometimes a welt that takes a day or two to fade. Mild redness or a run down feeling from the first thymosin alpha-1 doses in some.
- Week 1 to 2
LL-37 site reactions either settle with rotation or get worse. Fatigue, low grade fever or a flu like feeling after doses is a reason to stop LL-37, not push through. Nothing from thymosin alpha-1 to feel.
- Week 3 to 8
The window where any change in infection frequency, wound healing or recovery speed is first judged. There is no acute effect to track from thymosin alpha-1; lymphocyte subsets on bloodwork are the only objective measure. The LL-37 block usually ends here.
- Month 3 to 6
The window the hepatitis B trials used for thymosin alpha-1 response, and the earliest point at which a chronic infection goal can fairly be evaluated. If nothing has changed, continuing has no support.
Side effects and cautions
- ▲Injection site redness, swelling, warmth and pain from LL-37, often significant
- ▲Welts or firm lumps at LL-37 sites that last days
- ▲Fatigue or a flu like feeling after doses of either compound
- ▲Low grade fever or chills in a minority
- ▲Injection site redness, soreness or small lumps from thymosin alpha-1
- ▲Mild muscle aches, nausea, or a rash away from the injection site
- ■Psoriasis, rosacea, lupus or any autoimmune condition. LL-37 is a recognized driver of inflammation in these diseases, and thymosin alpha-1 raises Th1 activity. This is the clearest reason to skip the stack.
- ■Transplant recipients and anyone on immunosuppressants. The thymosin alpha-1 label advises against use after transplant, and LL-37 works against immunosuppressive therapy.
- ■Anyone expecting it to treat Lyme disease, long COVID or a diagnosed infection. There is no controlled evidence for any of these, and a real infection needs a clinician.
- ■Tested athletes. Both are treated as prohibited by WADA under S0, and athletes have been sanctioned for thymosin alpha-1.
- ■Anyone who cannot tolerate injection site reactions. LL-37 produces them in most people by design, and spreading, blistering or ulcerating sites are a reason to stop.
Thymosin alpha-1 on its own is a defensible choice for someone with a documented immune problem, a poor vaccine response or a chronic viral infection who understands that the trial benefits were modest and that a research vial is not the licensed product. Adding LL-37 turns a reasonable protocol into an experiment. The antimicrobial and biofilm findings are real in culture and unproven by any route in people, the injection site reactions are severe enough that many people stop within two weeks, and the peptide is a known driver of autoimmune skin and systemic disease. No trial has tested the pair, no human safety data exist for injected LL-37, and the chronic infection claims that drive the stack have no controlled support. Anyone with psoriasis, rosacea, lupus, a transplant, or an undiagnosed infection has a clear reason to avoid it. This page is educational and not medical advice; a chronic infection is a problem for an infectious disease clinician.
Thymosin Alpha-1 and LL-37: frequently asked
Is LL-37 safe to inject?
Nobody knows, and that is the honest answer. The only human trial of LL-37 was topical, on open leg ulcers, at low concentrations, and it found the highest concentration worked worse than the lower two. There are no trials of injected LL-37 in people and no published human safety data for that route. What is known is that it recruits immune cells and can damage host cell membranes at higher concentrations, which is why injection sites react the way they do. The general question is covered at are peptides safe.
Does thymosin alpha-1 and LL-37 work for Lyme disease?
There is no evidence that it does. No trial has tested either peptide for Lyme by any route, and no trial has tested the pair for anything. The LL-37 biofilm data are from culture dishes, and injected LL-37 is broken down quickly in serum. Thymosin alpha-1 has real trial data in hepatitis B, sepsis and vaccine response, none of which is Lyme. Anyone with a suspected tick borne infection needs testing and treatment, not this stack.
What is the thymosin alpha-1 dosage in this stack?
The same as on its own. The approved dosage for hepatitis B is 1.6 mg subcutaneously twice weekly for six months; vaccine trials used the same dose for a few weeks. Community protocols report 0.5 to 1.6 mg, two to three times weekly, for 4 to 12 weeks, with short daily courses of 5 to 7 days around an acute illness. The peptide dosage chart lists it alongside everything else.
Why does LL-37 cause such a reaction at the injection site?
Because that is its job. In the body LL-37 is released at sites of injury or infection to pull neutrophils and monocytes in and start inflammation. Injecting a bolus under the skin creates exactly that signal. Redness, warmth, swelling and pain for a day or two are commonly reported, and a quarter sized welt is not unusual. Rotating sites and starting at 50 mcg reduce it; nothing eliminates it. The peptide injection sites article covers rotation.
Can you take thymosin alpha-1 and LL-37 at the same time?
People do, in separate syringes. No interaction is known, and no trial has tested the pair, so compatibility is an assumption rather than a finding. The two run on different schedules anyway, thymosin alpha-1 twice weekly and LL-37 daily for a short block, so they only coincide on some days. Separate syringes keep LL-37 reactions traceable.
Is thymosin alpha-1 better than LL-37 for immune support?
By a wide margin. Thymosin alpha-1 is a licensed drug with randomized trials, thousands of patients and a mild side effect profile. LL-37 has one small topical trial and a lot of test tube data. Someone who wants immune support and has to pick one has an easy choice, and someone considering the pair should ask what LL-37 adds beyond inflamed injection sites. The full ranking is at best peptides for immune support.
Related reading
Gut lining repair and inflammation control
Cellular energy and antioxidant support
Same first name, nothing else in common. Which thymosin do you actually want?
Both are gut peptides. One repairs, one calms inflammation. Which problem do you have?
Safety
Safety
Guide
Sources
- Thymosin alpha 1 in the treatment of chronic hepatitis B: a meta-analysis. Alimentary Pharmacology and Therapeutics, 2001
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Critical Care, 2013
- Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair and Regeneration, 2014
- Human host defense peptide LL-37 prevents bacterial biofilm formation. Infection and Immunity, 2008
- Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 2007